Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methylphenidate in KBG Syndrome
NCT06465641Phase 4Recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Nov 2024
- Primary completion
- Jan 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of methylphenidate hydrochloride extended-release chewable tablet in KBG syndrome (KBG), attention deficit hyperactivity disorder (ADHD), sponsored by Radboud University Medical Center. Started Nov 2024; status: recruiting.
02
Drugs
methylphenidate hydrochloride extended-release chewable tablet
03
Conditions
KBG syndrome (KBG)attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT06465641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06465641.